MARKET

VOR

VOR

Vor Biopharma Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

22.56
+3.41
+17.81%
After Hours: 22.70 +0.14 +0.62% 17:45 05/18 EDT
OPEN
19.30
PREV CLOSE
19.15
HIGH
23.96
LOW
19.01
VOLUME
430.14K
TURNOVER
--
52 WEEK HIGH
63.62
52 WEEK LOW
18.11
MARKET CAP
781.51M
P/E (TTM)
-17.2122
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12)
Benzinga · 5d ago
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10)
Benzinga · 05/11 11:54
How Many Vor Biopharma Inc. (NASDAQ:VOR) Shares Do Institutions Own?
If you want to know who really controls Vor Biopharma Inc. ( NASDAQ:VOR ), then you'll have to look at the makeup of...
Simply Wall St. · 05/07 14:30
B.Riley Financial Thinks Vor Biopharma’s Stock is Going to Recover
In a report released yesterday, Justin Walsh from B.Riley Financial reiterated a Buy rating on Vor Biopharma (VOR), with a price target of $60.00. The
SmarterAnalyst · 05/07 06:45
Vor Biopharma EPS misses by $0.03
Vor Biopharma (VOR): Q1 GAAP EPS of -$0.67 misses by $0.03.Cash and cash equivalents of $262.6MPress Release
Seekingalpha · 05/06 21:25
Vor Reports First Quarter 2021 Financial Results and Provides Company Update
Health Canada clears the CTA for VOR33 clinical trial Vor to present on VOR33 manufacturing scale-up and in-depth genomic characterization at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting Successful completion of Initial Public Offerin...
GlobeNewswire · 05/06 20:39
64 Biggest Movers From Yesterday
Gainers
Benzinga · 05/05 09:59
Vor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT
An oral presentation on successful scale-up of GMP-like VOR33 manufacturing and a poster presentation on off-target editing are scheduled for Tuesday, May 11CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) is pleased to anno...
GlobeNewswire · 04/28 13:00
More
Forecast
Actual (K USD)
Estimate (K USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VOR. Analyze the recent business situations of Vor Biopharma Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VOR stock price target is 47.75 with a high estimate of 60.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 30.69M
% Owned: 88.59%
Shares Outstanding: 34.64M
TypeInstitutionsShares
Increased
0
0
New
48
30.69M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About VOR
Vor Biopharma Inc is a clinical-stage cell therapy company. The Company is engaged in combining a novel patient engineering approach with targeted therapies to provide solution for patients suffering from hematological malignancies. The Company develops engineered hematopoietic stem cell (eHSC) product candidate, VOR33, VCAR33, which together are the treatment paradigm for acute myeloid leukemia (AML) and other hematological malignancies. The Company’s platform provides treatment for both hematopoietic stem cell transplants and targeted therapies, such as antibody drug conjugates (ADCs), bispecific antibodies and CAR-T cell treatments, including CD33 CAR-T. The Company uses genome engineering technology to remove CD33 surface targets from hematopoietic stem cells (HSCs) to create VOR33. The Company’s eHSCs, such as VOR33, are designed to be used with therapeutics such as VCAR33, that would provide tumor-specific killing.

Webull offers kinds of Vor Biopharma Inc stock information, including NASDAQ:VOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VOR stock methods without spending real money on the virtual paper trading platform.